![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » J&J’s COVID-19 Vaccine Booster May Best Pfizer’s, Says Study
J&J’s COVID-19 Vaccine Booster May Best Pfizer’s, Says Study
A booster dose of the Johnson & Johnson (J&J) COVID-19 vaccine proved just as effective — or possibly more effective — for patients inoculated with the Pfizer-BioNTech vaccine as a booster with two doses of the Pfizer vaccine in a phase 2 study.
Funded in part by J&J, the small study at the Beth Israel Deaconess Medical Center in Boston, Mass., included just 24 participants.
The researchers found that a J&J booster increased neutralizing antibodies comparably to a Pfizer/BioNTech booster. But the findings also suggested a J&J booster increased T-cell responses more than an additional Pfizer/BioNTech dose.
Upcoming Events
-
21Oct